We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Xeris Biopharma Holdings Inc (XERS) USD0.0001

Sell:$1.62 Buy:$1.63 Change: $0.005 (0.31%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.005 (0.31%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.005 (0.31%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The Company has three commercial products: Gvoke, Keveyis and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Its product candidate also includes Ogluo (EU), Self-Administered Glucagon for prevention, Levothyroxine and XP-9164. The Company uses its non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize its products.

Contact details

180 N. Lasalle Street, Suite 1600
United States
+1 (302) 6587581

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$220.92 million
Shares in issue:
135.53 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Paul Edick
    Chairman of the Board, Chief Executive Officer
  • John Shannon
    President, Chief Operating Officer
  • Steven Prestrelski
    Co-Founder, Chief Scientific Officer
  • Steven Pieper
    Chief Financial Officer
  • Allison Wey
    Senior Vice President - Investor Relations and Corporate Communications
  • Kenneth Johnson
    Senior Vice President - Global Development and Medical Affairs
  • Beth Hecht
    Chief Legal Officer, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.